<DOC>
	<DOCNO>NCT01861106</DOCNO>
	<brief_summary>Background : - GATA2 deficiency disease cause mutation GATA2 gene . It cause different type leukemia disease . Researchers want see stem cell transplant use treat condition . A stem cell transplant give stem cell match donor ( relate unrelated ) recipient . It allow donor stem cell produce healthy bone marrow blood cell attack recipient cancer cell . Objectives : - To see stem cell transplant successful treat GATA2 mutation related condition . Eligibility : - Recipients 10 70 year age GATA2 deficiency . - Donors 6 70 year age match recipient . Design : - All participant screen physical exam medical history . Blood sample collect . Recipients image study test . - Donor participant provide stem cell treatment . Filgrastim injection allow cell collect blood . In case , bone marrow donation need provide stem cell . - Recipients chemotherapy radiation prepare transplant . On day transplant , receive donate stem cell . - Recipients stay hospital condition stable transplant . - Frequent blood test scan require first 6 month transplant , follow less frequent visit time .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplant GATA2 Mutations</brief_title>
	<detailed_description>Background : Genetic sporadic mutation one allele GATA2 gene lead syndrome term MonoMAC . MonoMAC characterize : 1 ) infection Mycobacterium Avium Complex ( MAC ) opportunistic infection , 2 ) deficiency monocyte , Blymphocytes , Natural Killer ( NK ) cell peripheral blood , 3 ) progression myelodysplastic syndrome ( MDS ) , chronic myelomonocytic leukemia ( CMML ) , acute myelogenous leukemia ( AML ) , 4 ) mutation one allele GATA2 patient . We propose evaluate efficacy safety allogeneic hematopoietic stem cell transplantation ( HSCT ) use different conditioning regimen different donor source post-transplant immunosuppressive regimen reconstitute normal hematopoiesis reverse disease phenotype patient mutation GATA2 , clinical syndrome MonoMAC . Objectives : Primary : ( NotEqual ) ( Cross ) To determine whether allogeneic HSCT approach reconstitute normal hematopoiesis reverse disease phenotype one year patient mutation GATA2 clinical syndrome MonoMAC . Eligibility : ( NotEqual ) ( Cross ) Recipients age 8-70 year old mutation GATA2 , clinical syndrome MonoMAC . Clinical history least one life-threatening infection . ( NotEqual ) ( Cross ) Have 10/10 9/10 match relate unrelated donor ( HLA -A , -B , -C , DRB1 , DQB1 high resolution type identify National Marrow Donor Program ) , haploidentical relate donor . Design : ( NotEqual ) ( Cross ) Patients mutation GATA2 , clinical syndrome MonoMAC , 10/10 match relate unrelated donor receive pre-transplant conditioning regimen consist fludarabine 40 mg/m2 IV daily 4 day day -6 , -5 , -4 , -3 , busulfan 3.2 mg/kg IV daily day -6 , -5 , -4 , -3 , HSCT day 0 . The busulfan dose adjust base upon test dose busulfan . If patient normal , favorable , intermediate cytogenetics , post-transplant GVHD prophylaxis consist cyclophosphamide 50 mg/kg IV daily 2 day day +3 +4 , along mycophenolate mofetil day +5 day +35 tacrolimus day +5 day 180 . If evidence GVHD , tacrolimus begin taper approximately day +180 . If patient unfavorable cytogenetic abnormality prior transplant , posttransplant GVHD prophylaxis consist methotrexate 5 mg/m2 IV day +1 , +3 , +6 , +11 tacrolimus daily day -3 day +180 . If evidence graftversus-host disease , tacrolimus stop approximately day +180 . ( NotEqual ) ( Cross ) Patients mutation GATA2 , clinical syndrome MonoMAC , 9/10 match relate unrelated donor receive pre-transplant conditioning regimen consist cyclophosphamide 14.5 mg/kg IV daily 2 day day -6 -5 , busulfan 3.2 mg/kg IV daily day -4 , -3 , ( clonal cytogenetic abnormality present , three day busulfan 3.2 mg/kg IV daily day -4 , -3 , -2 give ) , fludarabine 30 mg/m2 IV daily 5 day day -6 -2 , 200 cGy TBI day -1 , HSCT day 0 . The busulfan dose adjust base upon test dose busulfan . Post-transplant immunosuppression GVHD prophylaxis recipient 9/10 donor consist cyclophosphamide 50 mg/kg IV daily 2 day day +3 +4 , along mycophenolate mofetil day +5 day +35 tacrolimus day +5 approximately day 180 . If evidence graft-versus-host disease , tacrolimus stop approximately day +180 . ( NotEqual ) ( Cross ) Patients mutation GATA2 , clinical syndrome MonoMAC , haploidentical relate donor receive pre-transplant conditioning cyclophosphamide 14.5 mg/kg IV daily 2 day day -6 -5 , busulfan 3.2 mg/kg IV daily day -4 , -3 , ( clonal cytogenetic abnormality present , three day busulfan 3.2 mg/kg IV daily day -4 , -3 , -2 ) give , fludarabine 30 mg/m2 IV daily 5 day day -6 -2 , 200 cGy TBI day -1 , HSCT day 0 . The busulfan dose adjust base upon test dose busulfan . Post-transplant immunosuppression GVHD prophylaxis recipient haploidentical donor consist cyclophosphamide 50 mg/kg IV daily 2 day day +3 +4 , along mycophenolate mofetil day +5 day +35 tacrolimus day +5 day 180 . If evidence graft-versus-host disease , tacrolimus stop approximately day +180 .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : INCLUSION CRITERIA Recipient 1 . Patient age 870 year . 2 . Mutation GATA2 gene , evidence loss expression one allele GATA2 , cDNA analysis perform CLIA certify laboratory , clinical syndrome MonoMAC 3 . Clinical history least one lifethreatening infection and/or MDS International Prognostic Scoring System ( IPSS ) category Intermediate1 , Intermediate2 High . 4 . 10/10 9/10 HLAmatched relate unrelated donor , haploidentical relate donor . 5 . Patients may evidence MDS one peripheral blood cytopenia great 5 % blast le 10 % blast bone marrow absence filgrastim . 6 . Left ventricular ejection fraction &gt; 40 % , preferably 2D echo obtain within 28 day enrollment 7 . Creatinine : Adult patient : less equal 2.0 mg/dl creatinine clearance great equal 30 ml/min ; Pediatric patient ( &lt; 18 year old ) creatinine &lt; 1.5 mg/dL creatinine clearance &gt; 30 mL/min/1.73m ( 2 ) . 8 . Serum conjugate bilirubin &lt; 2.5 mg/dl ; serum ALT AST less equal 5 time upper limit normal 9 . Adequate central venous access potential . 10 . Written inform consent/assent obtain patient/parent legal guardian . 11 . Disease status : Patients refer remission evaluation . Should patient progressive disease , donor becomes available enrollment , patient refer back primary hematologistoncologist treatment . If course action best interest patient accord clinical judgment PI/LAI , patient may receive standard treatment malignant disease current study . If either setting , become apparent patient able proceed transplant , he/she must come study . RecipientSubjects receive standard therapy tell therapy , associate risk , benefit alternative propose therapy , availability receive treatment elsewhere , outside research protocol . EXCLUSION CRITERIA Recipient 1 . Patient age le 8 year old great 70 year old 2 . HIV infection . 3 . Chronic active hepatitis B . Patient may hepatitis B core antibody positive . For patient concomitant positive hepatitis B surface antigen , patient require hepatology consultation . The riskbenefit profile transplant hepatitis B discuss patient , eligibility determine PI Lead Associate Investigator . 4 . History psychiatric disorder may compromise compliance transplant protocol , allow appropriate inform consent . 5 . Active infection refractory antimicrobial therapy . 6 . Active CNS involvement malignancy ( patient know positive CSF cytology parenchymal lesion visible CT MRI ) . 7 . Pregnant lactating . 8 . Sexually active individual capable become pregnant unable unwilling use effective form ( ) contraception time enrol study 1 year posttransplant . Effective form contraception include one following : intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation/hysterectomy , partner vasectomy , barrier method , ( condom , diaphragm , cervical cap ) , abstinence . The effect breastmilk also unknown may harmful infant ; therefore , woman breast feed interval study entry one year posttransplant . Males protocol must use effective form contraception study entry , one year posttransplant . The effect transplant , radiation , medication use transplant may harmful fetus . 9 . Presence active malignancy another organ system hematopoietic , except drive virus case immune reconstitution transplant may control malignancy . 10 . No available 10/10 9/10 HLAmatched relate unrelated donor , 4/6 ( great ) match UCB unit ( ) total dose great equal 3.5 time 10 ( 7 ) TNC/kg , haploidentical relate donor . INCLUSION CRITERIA Matched Related Donor 1 . Related donor match 9/10 10/10 HLAA , B , C , DR , DQ loci high resolution type . 2 . Ability give inform consent 3 . Age 670 year 4 . No history lifethreatening opportunistic infection 5 . Adequate venous access peripheral apheresis , consent use temporary central venous catheter apheresis . 6 . Donors must HIV negative , hepatitis B surface antigen negative , hepatitis C antibody negative . This prevent possible transmission infection recipient . 7 . A donor lactating must willing able interrupt breastfeed substitute formula feed infant period filgrastim administration two day follow final dose . Filgrastim may secrete human milk , although bioavailability source know . 8 . No mutation GATA2 , case mutation GATA2 identify , recipient clinical syndrome MonoMAC , donor require clinical evidence MonoMAC . INCLUSIN CRITERIA Matched Unrelated Donor 1 . Unrelated donor match 10/10 9/10 HLAA , B , C , DRB1 , DQB1 loci high resolution type . 2 . The evaluation donor shall accordance exist NMDP Standard Policies Procedures . General donor inclusion criterion specify NMDP Standards . INCLUSION CRITERIA Haploidentical Related Donor 1 . A haploidentical donor relate donor share one haplotype common recipient HLA compatibility minimum 5 10 HLA locus match . The HLA locus test HLA A , B , Cw , DRB1 , DQB1 . A minimum number mismatch desirable ; however several option available selection donor base loci mismatch occur relative importance potential immunological function . Donorrecipient pair initially type molecularly provide low resolution typing ( antigenlevel ) aid selection potential donor . Upon review familial inheritance pattern , qualify HLA staff member review haplotype inheritance . High resolution ( allelelevel ) typing perform . Final selection donor consultation NCI physician qualify HLA personnel . Haploidentical related donor pediatric recipient must 6 year age old . If one haploidentical relate donor available , evaluate donor individually accord overall health , ABO matching , CMV , etc . select donor 2 . Age 670 year 3 . No history lifethreatening opportunistic infection 4 . Donors must HIV negative , hepatitis B surface antigen negative , hepatitis C antibody negative . This prevent possible transmission infection recipient . 5 . Haploidentical donor undergo marrow harvest general anesthesia . Subjects undergo anesthesia consultation prior enrollment . CD34 plus fraction determine . 6 . No mutation GATA2 , case mutation GATA2 identify , recipient clinical syndrome MonoMAC , donor require clinical evidence MonoMAC EXCLUSION CRITERIA Matched Related Donor 1 . Age less than6 year great 70 year . 2 . History psychiatric disorder opinion PI may compromise compliance transplant protocol , allow appropriate inform consent . 3 . History medical condition opinion PI constitute contraindication donation . 4 . History prior malignancy . However , cancer survivor undergo potentially curative therapy may consider stem cell donation casebycase basis . Risk/benefit transplant possibility transmit viable tumor cell time transplantation discuss patient . 5 . Donors must pregnant . Pregnancy absolute contraindication protocol . The effect cytokine administration fetus unknown . Donors childbearing potential must use effective method contraception . Effective form contraception include one following : intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation/hysterectomy , partner vasectomy , barrier method , ( condom , diaphragm , cervical cap ) , abstinence . 6 . Mutation GATA2 , evidence loss expression one allele GATA2 cDNA analysis perform CLIA certify laboratory , case mutation GATA2 identify , recipient clinical syndrome MonoMAC , donor exclude clinical syndrome MonoMAC . EXCLUSION CRITERIA Matched Unrelated Donor ) Failure qualify NMDP donor . EXCLUSION CRITERIA Haploidentical Related Donor 1 . Age le 6 year great 70 . 2 . HIV infection 3 . Chronic active hepatitis B. Donor may hepatitis core antibody positive . 4 . History psychiatric disorder opinion PI may compromise compliance transplant protocol , allow appropriate inform 5 . History medical condition opinion PI constitute contraindication donation . 6 . History prior malignancy . However , cancer survivor undergo potentially curative therapy may consider stem cell donation casebycase basis . The risk/benefit transplant possibility transmit viable tumor cell time transplantation discuss patient . 7 . Donors must pregnant . Pregnancy absolute contraindication protocol . The effect cytokine administration fetus unknown . Donors childbearing potential must use effective method contraception . Effective form contraception include one following : intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation/hysterectomy , partner vasectomy , barrier method , ( condom , diaphragm , cervical cap ) , abstinence . 8 . Mutation GATA2 , evidence loss expression one allele GATA2 Cdna analysis perform CLIA certify laboratory , case mutation GATA2 identify , recipient clinical syndrome MonoMAC , donor required clinical history MonoMAC</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 31, 2017</verification_date>
	<keyword>Allogeneic Donors</keyword>
	<keyword>Peripheral Blood Stem Cell</keyword>
	<keyword>Immunodeficiency</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>Haploidentical</keyword>
</DOC>